# GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

> **NCT04021992** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 48 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab

## Key facts

- **NCT ID:** NCT04021992
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-15
- **Primary completion:** 2023-07-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04021992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04021992, "GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04021992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*